The expression of smad signaling pathway in myocardium and potential therapeutic effects

Histology and Histopathology

Volumn 32, Issue 7, 2017, Pages 651-659

  Duan, Yuping ^a,b   Zhu, Wei ^a   Liu, Min ^b   Ashraf, Muhammad ^b   Xu, Meifeng ^b  

^a JIANGSU UNIVERSITY   (China)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

BMP; Myocardial infarction; Smad; TGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; CARDIAC MUSCLE; GENETICS; HEART; HEART INFARCTION; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; HEART; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 85017258064     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: 10.14670/HH-11-845     Document Type: Review

References (99)

1. Al-Shabanah O.A., Aleisa A.M., Hafez M.M., Al-Rejaie S.S., Al-Yahya A.A., Bakheet S.A., Al-Harbi M.M. and Sayed-Ahmed M.M. (2012). Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through tfg-beta/smad p53 pathway in rat model. Oxid. Med. Cell Longev. 2012, 619185.
2. Alfaro M.P., Vincent A., Saraswati S., Thorne C.A., Hong C.C., Lee E. and Young P.P. (2010). Sfrp2 suppression of bone morphogenic protein (bmp) and wnt signaling mediates mesenchymal stem cell (msc) self-renewal promoting engraftment and myocardial repair. J. Biol. Chem. 285, 35645-35653.
3. Araujo-Jorge T.C., Waghabi M.C., Hasslocher-Moreno A.M., Xavier S.S., Higuchi Mde L., Keramidas M., Bailly S. and Feige J.J. (2002). Implication of transforming growth factor-beta1 in chagas disease myocardiopathy. J. Infect. Dis. 186, 1823-1828.
4. Banach J., Gilewski W., Slomka A., Buszko K., Blazejewski J., Karasek D., Rogowicz D., Zekanowska E. and Sinkiewicz W. (2016). Bone morphogenetic protein 6 - a possible new player in pathophysiology of heart failure. Clin. Exp. Pharmacol. Physiol. 43, 1247-1250.
5. Bernal A., Perez L.M., De Lucas B., Martin N.S., Kadow-Romacker A., Plaza G., Raum K. and Galvez B.G. (2015). Low-intensity pulsed ultrasound improves the functional properties of cardiac mesoangioblasts. Stem Cell Rev. 11, 852-865.
6. Bjornstad J.L., Skrbic B., Marstein H.S., Hasic A., Sjaastad I., Louch W.E., Florholmen G., Christensen G. and Tonnessen T. (2012). Inhibition of smad2 phosphorylation preserves cardiac function during pressure overload. Cardiovasc. Res. 93, 100-110.
7. Bugyei-Twum A., Advani A., Advani S.L., Zhang Y., Thai K., Kelly D.J. and Connelly K.A. (2014). High glucose induces smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc. Diabetol. 13, 89.
8. Bujak M., Ren G., Kweon H.J., Dobaczewski M., Reddy A., Taffet G., Wang X.F. and Frangogiannis N.G. (2007). Essential role of smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 116, 2127-2138.
9. Cagavi E., Bartulos O., Suh C.Y., Sun B., Yue Z., Jiang Z., Yue L. and Qyang Y. (2014). Functional cardiomyocytes derived from isl1 cardiac progenitors via BMP4 stimulation. PloS one 9, e110752.
10. Chang S.A., Lee E.J., Kang H.J., Zhang S.Y., Kim J.H., Li L., Youn S.W., Lee C.S., Kim K.H., Won J.Y., Sohn J.W., Park K.W., Cho H.J., Yang S.E., Oh W.I., Yang Y.S., Ho W.K., Park Y.B. and Kim H.S. (2008). Impact of myocardial infarct proteins and oscillating pressure on the differentiation of mesenchymal stem cells: Effect of acute myocardial infarction on stem cell differentiation. Stem Cells 26, 1901-1912.
11. Chen L.L., Yin H. and Huang J. (2007). Inhibition of TGF-beta1 signaling by eNOs gene transfer improves ventricular remodeling after myocardial infarction through angiogenesis and reduction of apoptosis. Cardiovasc. Pathol. 16, 221-230.
12. Crabos M., Roth M., Hahn A.W. and Erne P. (1994). Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J. Clin. Invest. 93, 2372-2378.
13. Cvjeticanin B., Prutki M., Dumic-Cule I., Veir Z., Grgurevic L. and Vukicevic S. (2014). Possible target for preventing fibrotic scar formation following acute myocardial infarction. Med. Hypotheses 83, 656-658.
14. Dixon I.M., Hao J., Reid N.L. and Roth J.C. (2000). Effect of chronic AT(1) receptor blockade on cardiac smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc. Res. 46, 286-297.
15. Dobaczewski M., Bujak M., Li N., Gonzalez-Quesada C., Mendoza L.H., Wang X.F. and Frangogiannis N.G. (2010). Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ. Res. 107, 418-428.
16. Ebelt H., Hillebrand I., Arlt S., Zhang Y., Kostin S., Neuhaus H., Muller-Werdan U., Schwarz E., Werdan K. and Braun T. (2013). Treatment with bone morphogenetic protein 2 limits infarct size after myocardial infarction in mice. Shock 39, 353-360.
17. Edgley A.J., Krum H. and Kelly D.J. (2012). Targeting fibrosis for the treatment of heart failure: A role for transforming growth factor-beta. Cardiovasc. Ther. 30, e30-40.
18. Euler G. (2015). Good and bad sides of TGFbeta-signaling in myocardial infarction. Front. Physiol. 6, 66.
19. Flanders K.C. (2004). Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 85, 47-64.
20. Gabriel V.A. (2009). Transforming growth factor-beta and angiotensin in fibrosis and burn injuries. J. Burn Care Res. 30, 471-481.
21. Galvin K.M., Donovan M.J., Lynch C.A., Meyer R.I., Paul R.J., Lorenz J.N., Fairchild-Huntress V., Dixon K.L., Dunmore J.H., Gimbrone M.A. Jr, Falb D. and Huszar D. (2000). A role for smad6 in development and homeostasis of the cardiovascular system. Nat. Genet. 24, 171-174.
22. Goldstein J.A., Bogdanovich S., Beiriger A., Wren L.M., Rossi A.E., Gao Q.Q., Gardner B.B., Earley J.U., Molkentin J.D. and McNally E.M. (2014). Excess smad signaling contributes to heart and muscle dysfunction in muscular dystrophy. Hum. Mol. Genet. 23, 6722-6731.
23. Gong W., Yan M., Chen J., Chaugai S., Chen C. and Wang D. (2014). Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor beta-induced smad signaling. Front. Med. 8, 445-455.
24. Graf K. and Schaefer-Graf U.M. (2010). Is smad3 the key to inflammation and fibrosis in hypertensive heart disease? Hypertension 55, 1088-1089.
25. Gu J., Liu X., Wang Q.X., Tan H.W., Guo M., Jiang W.F. and Zhou L. (2012). Angiotensin II increases CTGF expression via MAPKs/TGF-beta1/traf6 pathway in atrial fibroblasts. Exp. Cell Res. 318, 2105-2115.
26. Hao J., Ju H., Zhao S., Junaid A., Scammell-La Fleur T. and Dixon I.M. (1999). Elevation of expression of smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J. Mol. Cell. Cardiol. 31, 667-678.
27. Hao J., Wang B., Jones S.C., Jassal D.S. and Dixon I.M. (2000). Interaction between angiotensin II and smad proteins in fibroblasts in failing heart and in vitro. Am. J. Physiol. Heart Circ. Physiol. 279, H3020-3030.
28. He Y., Zhou X., Zheng X. and Jiang X. (2013). Exogenous high-mobility group box 1 protein prevents postinfarction adverse myocardial remodeling through TGF-beta/smad signaling pathway. J. Cell. Biochem. 114, 1634-1641.
29. Heger J., Abdallah Y., Shahzad T., Klumpe I., Piper H.M., Schultheiss H.P., Schluter K.D., Schulz R., Euler G. and Dorner A. (2012). Transgenic overexpression of the adenine nucleotide translocase 1 protects cardiomyocytes against TGFbeta1-induced apoptosis by stabilization of the mitochondrial permeability transition pore. J. Mol. Cell. Cardiol. 53, 73-81.
30. Heldin C.H., Miyazono K. and ten Dijke P. (1997). TGF-beta signalling from cell membrane to nucleus through smad proteins. Nature 390, 465-471.
31. Huang W., Rubinstein J., Prieto A.R. and Wang D.H. (2010). Enhanced postmyocardial infarction fibrosis via stimulation of the transforming growth factor-beta-smad2 signaling pathway: Role of transient receptor potential vanilloid type 1 channels. J. Hypertens. 28, 367-376.
32. Huntgeburth M., Tiemann K., Shahverdyan R., Schluter K.D., Schreckenberg R., Gross M.L., Modersheim S., Caglayan E., Muller-Ehmsen J., Ghanem A., Vantler M., Zimmermann W.H., Bohm M. and Rosenkranz S. (2011). Transforming growth factor beta(1) oppositely regulates the hypertrophic and contractile response to beta-adrenergic stimulation in the heart. PloS one 6, e26628.
33. Ikeda Y., Aihara K., Sato T., Akaike M., Yoshizumi M., Suzaki Y., Izawa Y., Fujimura M., Hashizume S., Kato M., Yagi S., Tamaki T., Kawano H., Matsumoto T., Azuma H., Kato S. and Matsumoto T. (2005). Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin ii-induced cardiac fibrosis. J. Biol. Chem. 280, 29661-29666.
34. Imamura T., Takase M., Nishihara A., Oeda E., Hanai J., Kawabata M. and Miyazono K. (1997). Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389, 622-626.
35. Ishisaki A., Yamato K., Hashimoto S., Nakao A., Tamaki K., Nonaka K., ten Dijke P., Sugino H. and Nishihara T. (1999). Differential inhibition of smad6 and smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in b cells. J. Biol. Chem. 274, 13637-13642.
36. Isono M., Chen S., Hong S.W., Iglesias-de la Cruz M.C. and Ziyadeh F.N. (2002). Smad pathway is activated in the diabetic mouse kidney and smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem. Biophys. Res. Commun. 296, 1356-1365.
37. Jumabay M., Abdmaulen R., Urs S., Heydarkhan-Hagvall S., Chazenbalk G.D., Jordan M.C., Roos K.P., Yao Y. and Bostrom K.I. (2012). Endothelial differentiation in multipotent cells derived from mouse and human white mature adipocytes. J. Mol. Cell. Cardiol. 53, 790-800.
38. Katagiri T. and Watabe T. (2016). Bone morphogenetic proteins. Cold Spring Harb. Perspect. Biol. 8. a021899.
39. Khan S.A., Dong H., Joyce J., Sasaki T., Chu M.L. and Tsuda T. (2016). Fibulin-2 is essential for angiotensin ii-induced myocardial fibrosis mediated by transforming growth factor (TGF)-beta. Lab. Invest. 96, 773-783.
40. Kopp J., Preis E., Said H., Hafemann B., Wickert L., Gressner A.M., Pallua N. and Dooley S. (2005). Abrogation of transforming growth factor-beta signaling by smad7 inhibits collagen gel contraction of human dermal fibroblasts. J. Biol. Chem. 280, 21570-21576.
41. Kretzschmar M., Liu F., Hata A., Doody J. and Massague J. (1997). The TGF-beta family mediator smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes and Dev. 11, 984-995.
42. Letterio J.J. and Roberts A.B. (1998). Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16, 137-161.
43. Li Q., Xu Y., Li X., Guo Y. and Liu G. (2012). Inhibition of rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: Role of TGF-beta1-tak1. Toxicol. Lett. 211, 91-97.
44. Liu F., Pouponnot C. and Massague J. (1997). Dual role of the smad4/dpc4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev. 11, 3157-3167.
45. Liu F., Hata A., Baker J.C., Doody J., Carcamo J., Harland R.M. and Massague J. (1996). A human mad protein acting as a BMP-regulated transcriptional activator. Nature 381, 620-623.
46. Liu Y., Harmelink C., Peng Y., Chen Y., Wang Q. and Jiao K. (2014). Chd7 interacts with BMP r-smads to epigenetically regulate cardiogenesis in mice. Hum. Mol. Genet. 23, 2145-2156.
47. Long L., Ormiston M.L., Yang X., Southwood M., Graf S., Machado R.D., Mueller M., Kinzel B., Yung L.M., Wilkinson J.M., Moore S.D., Drake K.M., Aldred M.A., Yu P.B., Upton P.D. and Morrell N.W. (2015). Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat. Med. 21, 777-785.
48. Lucarini L., Durante M., Lanzi C., Pini A., Boccalini G., Calosi L., Moroni F., Masini E. and Mannaioni G. (2016). Hydamtiq, a selective parp-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-beta/smad signalling pathway. J. Cell. Mol. Med. (in press).
49. Luo J., Gao X., Peng L., Sun H. and Dai G. (2011). Effects of hydrochlorothiazide on cardiac remodeling in a rat model of myocardial infarction-induced congestive heart failure. Eur. J. Pharmacol. 667, 314-321.
50. Ma F., Li Y., Jia L., Han Y., Cheng J., Li H., Qi Y. and Du J. (2012). Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/smad activation and cardiac fibrosis induced by angiotensin II. PloS one 7, e35144.
51. Mao X., Debenedittis P., Sun Y., Chen J., Yuan K., Jiao K. and Chen Y. (2012). Vascular smooth muscle cell smad4 gene is important for mouse vascular development. Arterioscler. Thromb. Vasc. Biol. 32, 2171-2177.
52. Masaki M., Izumi M., Oshima Y., Nakaoka Y., Kuroda T., Kimura R., Sugiyama S., Terai K., Kitakaze M., Yamauchi-Takihara K., Kawase I. and Hirota H. (2005). Smad1 protects cardiomyocytes from ischemia-reperfusion injury. Circulation 111, 2752-2759.
53. Massaous J. and Hata A. (1997). TGF-beta signalling through the smad pathway. Trends Cell Biol. 7, 187-192.
54. Meng X.M., Chung A.C. and Lan H.Y. (2013). Role of the TGF-beta/BMP-7/smad pathways in renal diseases. Clin. Sci. 124, 243-254.
55. Miyazono K., Maeda S. and Imamura T. (2005). Bmp receptor signaling: Transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 16, 251-263.
56. Monzen K., Hiroi Y., Kudoh S., Akazawa H., Oka T., Takimoto E., Hayashi D., Hosoda T., Kawabata M., Miyazono K., Ishii S., Yazaki Y., Nagai R. and Komuro I. (2001). Smads, tak1, and their common target ATF-2 play a critical role in cardiomyocyte differentiation. J. Cell Biol. 153, 687-698.
57. Moustakas A., Souchelnytskyi S. and Heldin C.H. (2001). Smad regulation in TGF-beta signal transduction. J. Cell Sci. 114, 4359-4369.
58. Mungrue I.N., Zhao P., Yao Y., Meng H., Rau C., Havel J.V., Gorgels T.G., Bergen A.A., MacLellan W.R., Drake T.A., Bostrom K.I. and Lusis A.J. (2011). Abcc6 deficiency causes increased infarct size and apoptosis in a mouse cardiac ischemia-reperfusion model. Arterioscler. Thromb. Vasc. Biol. 31, 2806-2812.
59. Nakanishi N., Takahashi T., Ogata T., Adachi A., Imoto-Tsubakimoto H., Ueyama T. and Matsubara H. (2012). Parm-1 promotes cardiomyogenic differentiation through regulating the BMP/smad signaling pathway. Biochem. Biophys. Res. Commun. 428, 500-505.
60. Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L., Heuchel R., Itoh S., Kawabata M., Heldin N.E., Heldin C.H. and ten Dijke P. (1997). Identification of smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389, 631-635.
61. Palaniyandi S.S., Ferreira J.C., Brum P.C. and Mochly-Rosen D. (2011). PKCbetaII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responses. J Cell. Mol. Med. 15, 1769-1777.
62. Papangeli I. and Scambler P.J. (2013). Tbx1 genetically interacts with the transforming growth factor-beta/bone morphogenetic protein inhibitor smad7 during great vessel remodeling. Circ. Res. 112, 90-102.
63. Patterson G.I. and Padgett R.W. (2000). TGF beta-related pathways. Roles in caenorhabditis elegans development. Trends Genet. 16, 27-33.
64. Pokharel S., van Geel P.P., Sharma U.C., Cleutjens J.P., Bohnemeier H., Tian X.L., Schunkert H., Crijns H.J., Paul M. and Pinto Y.M. (2004). Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-Acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of smad2/3. Circulation 110, 3129-3135.
65. Ricard N., Ciais D., Levet S., Subileau M., Mallet C., Zimmers T.A., Lee S.J., Bidart M., Feige J.J. and Bailly S. (2012). BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood 119, 6162-6171.
66. Rodriguez-Vita J., Sanchez-Lopez E., Esteban V., Ruperez M., Egido J. and Ruiz-Ortega M. (2005). Angiotensin II activates the smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111, 2509-2517.
67. Rosenkranz S., Flesch M., Amann K., Haeuseler C., Kilter H., Seeland U., Schluter K.D. and Bohm M. (2002). Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am. J. Physiol. Heart Circ. Physiol. 283, H1253-1262.
68. Saika S., Ikeda K., Yamanaka O., Flanders K.C., Nakajima Y., Miyamoto T., Ohnishi Y., Kao W.W., Muragaki Y. and Ooshima A. (2005). Therapeutic effects of adenoviral gene transfer of bone morphogenic protein-7 on a corneal alkali injury model in mice. Lab. Invest. 85, 474-486.
69. Sanders L.N., Schoenhard J.A., Saleh M.A., Mukherjee A., Ryzhov S., McMaster W.G. Jr, Nolan K., Gumina R.J., Thompson T.B., Magnuson M.A., Harrison D.G. and Hatzopoulos A.K. (2016). BMP antagonist gremlin 2 limits inflammation after myocardial infarction. Circulation Res. 119, 434-449.
70. Scharpfenecker M., van Dinther M., Liu Z., van Bezooijen R.L., Zhao Q., Pukac L., Lowik C.W. and ten Dijke P. (2007). BMP-9 signals via ALK1 and inhibits BFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 120, 964-972.
71. Schieffer B., Wirger A., Meybrunn M., Seitz S., Holtz J., Riede U.N. and Drexler H. (1994). Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89, 2273-2282.
72. Schneiders D., Heger J., Best P., Michael Piper H. and Taimor G. (2005). Smad proteins are involved in apoptosis induction in ventricular cardiomyocytes. Cardiovasc. Res. 67, 87-96.
73. Shen X.C., Yang Y.P., Xiao T.T., Peng J. and Liu X.D. (2011). Protective effect of oxymatrine on myocardial fibrosis induced by acute myocardial infarction in rats involved in TGF-beta(1)-smads signal pathway. J. Asian Nat. Prod. Res. 13, 215-224.
74. Shi Y. and Massague J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700.
75. Sui X., Li D., Qiu H., Gaussin V. and Depre C. (2009). Activation of the bone morphogenetic protein receptor by h11kinase/hsp22 promotes cardiac cell growth and survival. Circ. Res. 104, 887-895.
76. Suzuki A., Chang C., Yingling J.M., Wang X.F. and Hemmati-Brivanlou A. (1997). Smad5 induces ventral fates in xenopus embryo. Dev. Biol. 184, 402-405.
77. Tandon A., Sharma A., Rodier J.T., Klibanov A.M., Rieger F.G. and Mohan R.R. (2013). BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo. PloS one 8, e66434.
78. Tseliou E., Reich H., de Couto G., Terrovitis J., Sun B., Liu W. and Marban E. (2014). Cardiospheres reverse adverse remodeling in chronic rat myocardial infarction: Roles of soluble endoglin and TGF-beta signaling. Basic Res. Cardiol. 109, 443.
79. Tsukamoto S., Mizuta T., Fujimoto M., Ohte S., Osawa K., Miyamoto A., Yoneyama K., Murata E., Machiya A., Jimi E., Kokabu S. and Katagiri T. (2014). Smad9 is a new type of transcriptional regulator in bone morphogenetic protein signaling. Sci. Rep. 4, 7596.
80. Upton P.D., Davies R.J., Tajsic T. and Morrell N.W. (2013). Transforming growth factor-beta(1) represses bone morphogenetic protein-mediated smad signaling in pulmonary artery smooth muscle cells via smad3. Am. J. Respir. Cell Mol. Biol. 49, 1135-1145.
81. Vilahur G., Juan-Babot O., Pena E., Onate B., Casani L. and Badimon L. (2011). Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J. Mol. Cell. Cardiol. 50, 522-533.
82. Wang B., Hao J., Jones S.C., Yee M.S., Roth J.C. and Dixon I.M. (2002). Decreased smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am. J. Physiol. Heart Circ. Physiol. 282, H1685-1696.
83. Wang L.F., Zhang L., Zhang R.Y. and Li S.J. (2005). Relationship between expression of smad and ventricular remodeling after myocardial infarction in rats. Zhonghua Xin Xue Guan Bing Za Zhi 33, 932-935. (in chinese).
84. Wang Z.F., Wang N.P., Harmouche S., Philip T., Pang X.F., Bai F. and Zhao Z.Q. (2013). Postconditioning promotes the cardiac repair through balancing collagen degradation and synthesis after myocardial infarction in rats. Basic Res. Cardiol. 108, 318.
85. Wei H., Bedja D., Koitabashi N., Xing D., Chen J., Fox-Talbot K., Rouf R., Chen S., Steenbergen C., Harmon J.W., Dietz H.C., Gabrielson K.L., Kass D.A. and Semenza G.L. (2012). Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-beta signaling. Proc. Natl. Acad. Sci. USA 109, E841-850.
86. Wei L.H., Huang X.R., Zhang Y., Li Y.Q., Chen H.Y., Yan B.P., Yu C.M. and Lan H.Y. (2013). Smad7 inhibits angiotensin ii-induced hypertensive cardiac remodelling. Cardiovasc. Res. 99, 665-673.
87. Weiskirchen R. and Meurer S.K. (2013). BMP-7 counteracting TGF-beta1 activities in organ fibrosis. Front. Biosci. 18, 1407-1434.
88. Wu X.L., Zeng W.Z., Jiang M.D., Qin J.P. and Xu H. (2008). Effect of oxymatrine on the TGFbeta-smad signaling pathway in rats with CCL4-induced hepatic fibrosis. World J. Gastroenterol. 14, 2100-2105.
89. Wu X., Sagave J., Rutkovskiy A., Haugen F., Baysa A., Nygard S., Czibik G., Dahl C.P., Gullestad L., Vaage J. and Valen G. (2014). Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart. Life Sci. 97, 145-154.
90. Xiang F.L., Guo M. and Yutzey K.E. (2016). Overexpression of tbx20 in adult cardiomyocytes promotes proliferation and improves cardiac function after myocardial infarction. Circulation 133, 1081-1092.
91. Xiao Z., Zhang J., Peng X., Dong Y., Jia L., Li H. and Du J. (2014). The notch gamma-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-beta/smad2/3 signaling pathway activation. Int. J. Biochem. Cell Biol. 55, 65-71.
92. Xiao X., Chang G., Liu J., Sun G., Liu L., Qin S. and Zhang D. (2016). Simvastatin ameliorates ventricular remodeling via the TGFbeta1 signaling pathway in rats following myocardial infarction. Mol. Med. Rep. 13, 5093-5101.
93. Xu F., Liu C., Zhou D. and Zhang L. (2016). TGF-beta/smad pathway and its regulation in hepatic fibrosis. J. Histochem. Cytochem. 64, 157-167.
94. Yagi S., Aihara K., Ikeda Y., Sumitomo Y., Yoshida S., Ise T., Iwase T., Ishikawa K., Azuma H., Akaike M. and Matsumoto T. (2008). Pitavastatin, an HGM-CoA reductase inhibitor, exerts enos-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ. Res. 102, 68-76.
95. Yang Y.Z., Fan T.T., Gao F., Fu J. and Liu Q. (2015). Exogenous cytochrome C inhibits the expression of transforming growth factor-beta1 in a mouse model of sepsis-induced myocardial dysfunction via the smad1/5/8 signaling pathway. Mol. Med. Rep. 12, 2189-2196.
96. Zeng W., Chen W., Leng X., He J.G. and Ma H. (2009). Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/smad signaling pathway in rabbits. Biochem. Biophys. Res. Commun. 389, 138-144.
97. Zhai Y., Gao X., Wu Q., Peng L., Lin J. and Zuo Z. (2008). Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/smad 7 expression in the spontaneously hypertensive rats. Eur. J. Pharmacol. 587, 196-203.
98. Zhang Y., Shao L., Ma A., Guan G., Wang J., Wang Y. and Tian G. (2014). Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-beta1/smad signal pathway. Hypertens. Res. 37, 43-49.
99. Zhao M., Zheng S., Yang J., Wu Y., Ren Y., Kong X., Li W. and Xuan J. (2015). Suppression of TGF-beta1/smad signaling pathway by sesamin contributes to the attenuation of myocardial fibrosis in spontaneously hypertensive rats. PloS One 10, e0121312.